Participated · Seed · Aug 2026

Nbryo develops an integrated IVF platform that combines biotechnology with digital tools to deliver scalable bovine reproductive solutions. Over the past 12 months the company commercialised its embryo multiplication technology and established a growing base of paying customers and commercial relationships with leading Australian beef producers. The business positions its offerings to improve reproductive efficiency and accelerate genetic improvement in herds. The recent A$20 million seed round, including government-backed Sowing the Seeds Fund support, is intended to fund the company's next phase of growth and further commercialisation. Nbryo has attracted investment from specialist agricultural investors and philanthropic capital, including the Gates Foundation, AgriZero, Tenacious Ventures and QIC Ventures.

Participated · Equity · Jun 2026

Leyden Labs is developing a Mucosal Protection Platform that administers broadly protective antibodies directly to the respiratory mucosa via intranasal sprays. The company targets protection against influenza, coronaviruses and other respiratory virus families with candidates designed to retain activity even as viruses mutate. Leyden Labs positions mucosal delivery as protection “at the gate,” aiming to prevent initial infection and subsequent illness where systemic vaccines or antibodies may be less effective. The approach is also presented as potentially beneficial for people with weakened immune systems because it does not rely on a fully functional systemic immune response. Leyden Labs is advancing its programs through clinical development and is focused on enabling global access to its products. The company recently added Ben Verwaayen to its Supervisory Board as it scales development and access efforts.

Led · Grant · Jun 2026

Converge Bio develops generative AI computational labs and virtual cell simulation applications engineered to optimize antibody design, gene expression, and biological target selection. The company is led by CEO Dov Gertz, CSO Dr. Iddo Weiner, and CTO Oded Kalev and is based in Boston, Massachusetts. Converge has advanced two independent drug programs through Phase 2 clinical trials and holds a licensed CRISPR discovery patent associated with Nobel laureate Jennifer Doudna. It has also established a 37-month cross-industry research partnership. With the $2.5 million Gates Foundation grant, Converge plans to expand its drug modeling platform into crop genomics, build multimodal long-context DNA foundation models, and accelerate breeding timelines for climate-resilient plants.

Participated · Series A · May 2026

Kanvas Biosciences develops a spatial biology platform for microbiome drug screening, discovery and manufacturing aimed at accelerating live biotherapeutics development. The company’s lead program is KAN-001, an immuno-oncology candidate for which the recent Series A will fund clinical trials. Kanvas intends to use proceeds to advance commercial partnerships alongside clinical development. Its core technology was initially developed at Cornell University and is exclusively licensed. The company is led by CEO Matthew Cheng. The articles do not report revenue, user metrics, founding year, or prior financing details.

Led · Grant · Mar 2026

Rainbow Crops develops Trait Foundry™, an AI-driven platform that combines artificial intelligence, multiplex genome editing, precision breeding, and automated phenotyping to identify and evaluate genetic variant combinations linked to complex agronomic traits. The company aims to accelerate development of higher-performing, more resilient crop varieties and has demonstrated proof of concept in corn. Rainbow Crops plans to deploy its platform across additional crops and expand its scientific and technical teams to scale its capabilities. It raised €9.7 million in an oversubscribed seed round to fund further development of its AI-assisted multiplex genome editing and broader deployment. The company frames its work against climate volatility, fluctuating input costs, and evolving regulatory support for gene editing technologies.